Skip to content

OxSonics Wins The Gold Award at the 2019 Tech Tour Contest Grand Final

OxSonics CEO Interview At BIO Investor Forum San Francisco

SonoTran® Particles Patent Granted in the United States and Japan

OxSonics Co-Founder & CSO Professor Constantin Coussios elected as a Fellow of the Royal Academy of Engineering

OxSonics® Wins European Healthtech Investment Forum Competition

OxSonics’ CEO Interview At BIO CEO Investor Conference

OxSonics Launches New Website & Renames as OxSonics Therapeutics

Oxford, UK – 10th December 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that from over 2,500 companies it has been judged the ultimate winner of the European-wide Healthtech 2019 Tech Tour Contest Final.

The 13th edition of the Tech Tour Contest Final 2019 – Europe’s leading network and investment event for high-growth technological start-ups, venture capital investors and technological corporations took place on 9-10 December 2019 in Essen, Germany.

The 125 presenting companies were invited as the ‘top-rated companies’ of the Tech Tour European Venture Contest, that took place throughout 2019 in 20 regional or sector–focused qualifying events involving over 2,500 individual companies. These top 125 were first judged by panels of investors to find a shortlist of 17 from 125 and then through a second round of “pitch battle” in front of an enlarged judging panel to find the ultimate winner in healthtech. OxSonics came top in all stages of the competition and secured 1st Place GOLD in the healthtech category.

Colin Story, CEO, commented: “This is a truly amazing result for OxSonics – to be judged the winner amongst so many healthtech companies across the whole of Europe is something to be truly proud of. This success is testament to the world leading and highly innovative technology OxSonics is developing and the first-class R&D, regulatory and commercial teams at OxSonics taking this technology forward for the benefit of patients. We are truly delighted by this achievement.”

The Tech Tour press release can be viewed here.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

About TechTour

Founded in 1998, Tech Tour is a unique cross-border platform for growing and emerging innovative tech companies on their way to investment and funding – _from the idea to the success story. The platform supports innovative companies and their projects through online community space and in person at 25 networking events that we organise each year. Tech Tour is well known in the venture capital market with its 20-years of experience across Europe and the Middle East, and planning to enlarge our scope of work to China. For more information please visit: www.techtour.com.

Oxford, UK – 22nd October 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer presented at the 2019 BIO Investor Forum in San Francisco. Colin Story, CEO, was interviewed at the conference, and a link to the interview can be viewed here.

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

SonoTran® Particles Patent Granted in the United States and Japan

Oxford, UK – 15th October 2019 – OxSonics therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that a patent protecting its SonoTran Particles has issued in the US and is proceeding to grant in Japan.

The granted patent claims relate not only to morphological features and methods of production of the SonoTran Particles, but also to their therapeutic and diagnostic use. The patent has today been issued by the US patent office and has also been allowed, and therefore is proceeding to grant, at the Japanese patent office.

Colin Story, CEO commented: “We’re very pleased to see the SonoTran Particle patent applications proceed to grant. In conjunction with the know-how associated with their GMP manufacture, this key proprietary asset is now broadly protected. During the past 2 years patents covering the company’s ‘see as you treat’ technology have also granted across all major territories. The company now has the benefit of combined protection of consumable and hardware components of its ground-breaking platform technology.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

OxSonics Co-Founder & CSO Professor Constantin Coussios elected as a Fellow of the Royal Academy of Engineering

Oxford, UK – 30th September 2019 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that co-founder and Chief Scientific Officer, Professor Constantin Coussios has been elected as a Fellow of the Royal Academy of Engineering.

Professor Constantin Coussios has been elected a Fellow of the Royal Academy of Engineering in recognition of his outstanding and continuing contributions to biomedical engineering. As well as being Professorial Fellow of Engineering Science, Constantin holds the first Statutory Chair in Biomedical Engineering at the University of Oxford, is the Director of the Institute of Biomedical Engineering (IBME), and a co-founder of OxSonics, OrthoSon and OrganOx.

Colin Story, CEO commented: “OxSonics owes its foundation to the ground-breaking developments made at the IBME of which Constantin is Director. This award recognizes Constantin’s tremendous contributions to the field of Biomedical Engineering as a whole and further validates Oxford as a worldwide centre of excellence for therapeutic ultrasound and drug delivery.”

See the following links for more information:

IBME News

Magdalen College News

Royal Academy of Engineering About Us

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

About the Royal Academy of Engineering

We bring together the most successful and talented engineers from across the profession – our Fellows – to advance and promote excellence in engineering for the benefit of society.

We have three strategic priorities: make the UK the leading nation for engineering innovation and businesses, address the engineering skills crisis, and position engineering at the heart of society.

We are a national academy with a global outlook.

For more information please visit www.raeng.org.uk.

Oxford, UK – 13th March 2019 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer presented at the 2019 European Healthtech Investment Forum in Helsinki.

OxSonics was one of 40 companies selected to present at the meeting out of an original 136 companies that applied. An expert panel of reviewers selected OxSonics as 1 of 10 winning companies at the event based on the quality of the investment presentation and proposition given at the meeting. Each of the 10 winning companies was awarded a finalist position in the 13th European Venture Contest to be held in Dusseldorf in December 2019.

Commenting on the win, Colin Story, CEO wrote: “We’re very pleased to be one of ten companies out of an original 136 to win a finalist position in this European-wide competition. All entrants are judged on the case for future investment and how this case is presented to the expert judging panels. The judges were quick to identify with the major clinical and commercial opportunity that our drug delivery platform, SonoTran®, offers. This further validation of the opportunity is testament to the hard work and dedication offered by everyone at OxSonics and many of our very supportive collaborators.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

OxSonics’ CEO Interview At BIO CEO Investor Conference

Oxford, UK – 11th February 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer presented at the 2019 BIO CEO Investor Conference in New York.

Colin Story, CEO, was interviewed at the conference, and a link to the interview can be viewed here: https://www.youtube.com/watch?v=vzj-SEph4xc 

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.

OxSonics Launches New Website & Renames as OxSonics Therapeutics 

Oxford, UK – 7th January 2019 – OxSonics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the launch of its new website and its new name “OxSonics Therapeutics”.

Colin Story, CEO, commented: “OxSonics Therapeutics innovative drug delivery platform is designed to deliver significant therapeutic advantages to those patients most in need, as such, the name ‘OxSonics Therapeutics’ better reflects our values and vision as a company.”

“Because our approach has the major advantage of not requiring any drug modification we can employ a hybrid business model. We will apply our technology to in-market oncology agents but also to collaborate with drug developers under strategic co-development partnerships – our new website provides more information to prospective partners.”

“Our vision as a company is to provide life changing therapies to those facing some of the toughest cancers – those patients with solid tumours. We enter the clinical arena next year where we begin to turn this vision into reality.”

– ENDS –

About OxSonics Therapeutics

OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.

The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.

OxSonics is based in Oxford in the UK.

For more information please visit: www.oxsonics.com.